Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5261 Target Snapshot

Serine/threonine-protein kinase TAO1 · SINGLE PROTEIN · Homo sapiens

1,657Compounds
227Assays
17Approved Drugs
1,445.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q7L7X3. Use UniProt Q7L7X3 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q7L7X3 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase TAO1 as ChEMBL target CHEMBL5261, mapped to UniProt Q7L7X3. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase TAO1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5261
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q7L7X3
Serine/threonine-protein kinase TAO1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Serine/threonine-protein kinase TAO1 is the right protein anchor across sources, using UniProt Q7L7X3 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein kinase TAO1
UniProt AccessionQ7L7X3
Component TypeProtein
Sequence Length1001 aa

Serine/threonine-protein kinase TAO1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Serine/threonine-protein kinase TAO1, mapped to UniProt Q7L7X3. Sequence length is 1001 aa.

Mapped IDQ7L7X3
Review nameSerine/threonine-protein kinase TAO1
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

17
Approved
9
Phase III
23
Phase II
16
Phase I
Assay Mix

Activity Type Distribution

IC50218.0
KI891.0
KD336.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL388978 9.35 Kd 0.45 Preclinical
CHEMBL388978 9.33 IC50 0.469 Preclinical
CHEMBL3544966 8.7 Kd 2.0 Preclinical
CHEMBL49120 8.2 Ki 6.31 Preclinical
CHEMBL1980995 8.0 Ki 10.0 Preclinical
CHEMBL5653589 7.93 Kd 11.86 Preclinical
CHEMBL4576489 7.82 Kd 15.0 Preclinical
CHEMBL2006715 7.8 Ki 15.85 Preclinical
CHEMBL3688339 7.77 Kd 17.0 Preclinical
CHEMBL2334586 7.7 IC50 20.0 Preclinical
Distribution

pChEMBL Value Distribution

140
5.0
122
5.5
126
6.0
52
6.5
74
7.0
15
7.5
2
8.0
2
8.5
3
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

ABEMACICLIB
CHEMBL3301610
Approved 2017
BRIGATINIB
CHEMBL3545311
Approved 2017
PALBOCICLIB
CHEMBL189963
Approved 2015
PAZOPANIB
CHEMBL477772
Approved 2009
SUNITINIB
CHEMBL535
Approved 2006
DASATINIB
CHEMBL5416410
Approved 2006
SORAFENIB
CHEMBL1336
Approved 2005
Assay Landscape

Assay Landscape

227
Total Assays
363
Tested Compounds
2
Assay Types
Binding — 226 assays, 127 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 174 43 6.5
assay format 22 60 6.9
cell-based format 21 2 7.7
subcellular format 9 22 6.0
Functional — 1 assays, 363 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 363 5.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine